Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), headquartered in Marlborough, Massachusetts, is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary INTASYL™ siRNA gene silencing technology is at the forefront of its efforts to enhance the effectiveness of immune cells in targeting and destroying tumor cells.
Phio's core product pipeline includes:
- PH-762: Targets the checkpoint protein PD-1 on immune cells, enhancing their ability to attack tumors. Currently in Phase 1b clinical trials, PH-762 is being tested for its efficacy in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
- PH-804: Focuses on the suppressive immune receptor TIGIT, present on T cells and natural killer cells, to bolster immune responses against cancer.
- PH-790: Aims to silence the PD-L1 protein, which normally prevents immune cells from attacking non-harmful cells, thereby boosting the body's natural defenses against cancer.
Phio Pharmaceuticals collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München to advance their research and development efforts. The company's financial health, as of the latest reports, shows a cash position of $6.5 million, with a significant reduction in research and development expenses aimed at transitioning from discovery to product development.
Phio's latest updates include the presentation of new data on PH-762 at various scientific conferences and the initiation of new partnerships. These efforts underscore Phio's commitment to delivering cutting-edge cancer treatments and improving patient outcomes.
For more details, visit the company's website at www.phiopharma.com.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced promising results from a study showcased at the ESMO Congress 2021. The study demonstrated that the INTASYL technology could cure tumors and elicit durable systemic immunity in a preclinical model targeting PD-1 and BRD4. Specifically, 83% of the treated animals showed complete tumor response, even with low dosage therapy. This research highlights INTASYL's potential as a versatile immuno-oncology therapeutic platform, with further clinical trials anticipated to validate its efficacy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13 to 15, 2021. Dr. Gerrit Dispersyn, President & CEO, will present on September 13 at 7:00 AM ET. A webcast of the presentation will be available, with replays accessible on the company's website for 90 days. Phio focuses on developing immuno-oncology therapeutics using its proprietary INTASYL platform, aimed at enhancing immune response against tumors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced that it will present new clinical study data at the ESMO Virtual Congress 2021 from September 16-21, 2021. The presentation will focus on dual targeting PD-1 and BRD4 using the company's proprietary INTASYL self-delivering RNAi platform, aiming to elicit persistent anti-tumor immunity following tumor resolution. The abstract number for this presentation is #4154. Archived details will be available on the Company's website in the Investors section.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q2 2021, showing a net loss of $2.7 million. The company has $29.4 million in cash, sufficient to fund operations through Q2 2023. Phio is advancing its INTASYL™ platform, with promising preclinical data for its lead asset, PH-762, aimed at PD-1 in cancer treatment. Clinical trials are set to begin in 2022, with expected milestones including first-in-human studies for melanoma. R&D expenses increased to $1.7 million, reflecting expanded clinical preparation.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in a Fireside Chat with H.C. Wainwright on July 12, 2021, at 11 a.m. Eastern Time. The event aims to discuss the company’s advancements in immuno-oncology therapeutics utilizing its INTASYL™ RNAi platform, designed to boost immune responses against tumors. Interested listeners should register in advance to access the live audio. The webcast will be archived for 90 days on the company’s website. For more information on Phio's innovative therapies, visit their site.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the rescheduling of its fireside chat with H.C. Wainwright, originally set for June 22, 2021. The new date is July 12, 2021, at 11 a.m. Eastern Time. Phio focuses on developing immuno-oncology therapeutics using its proprietary self-delivering RNAi (INTASYL™) platform, aimed at enhancing immune response against tumors. Investors can expect more details on the rescheduled event soon.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces CEO Dr. Gerrit Dispersyn's participation in two key virtual events: the AGP Summer Healthcare Symposium on June 17, 2021 and a fireside chat hosted by H.C. Wainwright on June 22, 2021. These platforms will highlight the company's innovative self-delivering RNAi (INTASYL™) therapeutic platform, which aims to enhance immuno-oncology treatments. Interested parties can register for the fireside chat and access future webcasts via the company’s website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced positive in vivo study results at the June 2021 ASCO Annual Meeting, showcasing its INTASYL™ RNAi therapy platform's efficacy in targeting BRD4 and PD-1 proteins. The dual-targeting approach led to complete tumor responses in 83% of tested mice, outperforming conventional treatments like JQ-1 and anti-PD-1 monoclonal antibodies. The study also indicated a superior safety profile for the INTASYL treatment. These findings emphasize INTASYL's potential in improving immuno-oncology therapies.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported financial results for Q1 2021, highlighting strong momentum in its pipeline. The company has significant data supporting its INTASYL compounds, showing potential to enhance CAR-T therapy efficacy. A clinical study for PH-762 in advanced melanoma is set to commence in Q4 2021, conducted at the Gustave Roussy Institute. Cash reserves reached $32.7 million, sufficient to fund operations into Q2 2023, despite a net loss of $3.4 million for the quarter. R&D expenses rose to $2.6 million, reflecting increased preclinical study costs.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising in vivo data on May 11, 2021, indicating that its compound PH-762 significantly boosts the antitumor efficacy of HER2-targeted CAR-T cells against solid tumors, particularly in a mouse model of ovarian cancer. The results show approximately 90% PD-1 silencing in HER2CART cells, enhancing their effectiveness without affecting cell viability. This breakthrough could improve T cell-based immunotherapies, addressing challenges faced by traditional CAR T-cell therapies in solid tumors.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What does Phio Pharmaceuticals Corp. do?
What is INTASYL™ technology?
What are Phio's key products?
Who are Phio's collaboration partners?
What recent achievements has Phio Pharmaceuticals announced?
What is the financial condition of Phio Pharmaceuticals?
What is PH-762?
What cancers is PH-762 being tested for?
What is the significance of INTASYL™ technology?
Where can I find more information about Phio Pharmaceuticals?
